BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1651 related articles for article (PubMed ID: 26281148)

  • 21. A refractory case of subclinical antibody-mediated rejection due to anti-HLA-DQ antibody in a kidney transplant patient.
    Fujimoto T; Nakada Y; Yamamoto I; Kobayashi A; Tanno Y; Yamada H; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():81-5. PubMed ID: 26031594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of recipients of human leukocyte antigen incompatible kidney transplants who underwent desensitization at King Fahad Specialist Hospital, Dammam, Saudi Arabia.
    Idris MA; Hossain A; Muntasir MA; Marmi A; Aldajani AA; Aljamaan YM; Akhtar M; Housawi A
    Saudi J Kidney Dis Transpl; 2017; 28(3):499-506. PubMed ID: 28540885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Alemtuzumab Induction in Highly Sensitized Pediatric Renal Transplant Recipients.
    Kim IK; Choi J; Vo AA; Kang A; Patel M; Toyoda M; Mirocha J; Kamil ES; Cohen JL; Louie S; Galera O; Jordan SC; Puliyanda DP
    Transplantation; 2017 Apr; 101(4):883-889. PubMed ID: 27495773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Intervention in Living Kidney Transplantation Based on Dynamic Monitoring of Donor Specific Antibodies.
    Chen Y; Li LY; Lou XY; Wang H; Zhang L; Zhu YH
    Clin Transpl; 2014; ():205-8. PubMed ID: 26281146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
    Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
    Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection.
    Jordan SC; Vo AA; Toyoda M; Tyan D; Nast CC
    Pediatr Transplant; 2005 Apr; 9(2):155-61. PubMed ID: 15787786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers.
    Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Avila Bernabeu A; Crespo Albiach J; Molina Vila P; Beltrán Catalan S; Pallardó Mateu L
    Transplant Proc; 2016 Nov; 48(9):2880-2883. PubMed ID: 27932097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hidden perils in a highly sensitized kidney transplant recipient.
    Ford S; Summers S; Cantwell L; Mulley W
    Nephrology (Carlton); 2012 Apr; 17 Suppl 1():9-11. PubMed ID: 22497647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
    Peng ZG; Tian J
    Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late acute humoral rejection in low-risk renal transplant recipients induced with an interleukin-2 receptor antagonist and maintained with standard therapy: preliminary communication.
    Morales J; Contreras L; Zehnder C; Pinto V; Elberg M; Araneda S; Herzog C; Calabran L; Aguiló J; Ferrario M; Buckel E; Fierro JA
    Transplant Proc; 2011; 43(6):2295-9. PubMed ID: 21839258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients.
    Brokhof MM; Sollinger HW; Hager DR; Muth BL; Pirsch JD; Fernandez LA; Bellingham JM; Mezrich JD; Foley DP; D'Alessandro AM; Odorico JS; Mohamed MA; Vidyasagar V; Ellis TM; Kaufman DB; Djamali A
    Transplantation; 2014 Mar; 97(6):612-7. PubMed ID: 24531846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Panel-reactive antibody levels and renal transplantation rates in sensitized patients after desensitization and human leucocyte antigen amino acid residue matching.
    Shang W; Dong L; Feng G; Wang Y; Pang X; Li J; Liu L; Zhang W
    J Int Med Res; 2013 Aug; 41(4):1333-41. PubMed ID: 23780877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of HLA Antibodies in HLA Mismatched Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhang X; Wang J; Zhou Z; Zhang Y; Liu H; Tong C; Yu C; Lu Y; Zhao Y; Xiong M; Zhou JR; Juan S; Liu DY; Wei Z; Zhang J; Wu T; Lu DP
    Clin Transpl; 2014; ():245-50. PubMed ID: 26281152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
    Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
    Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.